search

35 Facts About ABBV Stock

Tanitansy Lambeth

Written by Tanitansy Lambeth

Published: 11 Aug 2025

Expert Verified Editorial Guidelines
35-facts-about-abbv-stock
Source: Marketbeat.com

ABBV stock has been a hot topic among investors, but what makes it so intriguing? AbbVie Inc. (ABBV), a global biopharmaceutical company, has consistently drawn attention due to its innovative treatments and strong market presence. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie has since made significant strides in the healthcare sector. With a diverse portfolio that includes blockbuster drugs like Humira, Imbruvica, and Rinvoq, AbbVie has positioned itself as a leader in the industry. Investors often look at factors like dividend yield, market cap, and revenue growth when evaluating ABBV stock. But beyond the numbers, understanding the company's strategic moves, such as mergers and acquisitions, can provide deeper insights. Curious about what else makes ABBV stock stand out? Here are 35 facts that will give you a comprehensive look at this pharmaceutical giant.

Table of Contents
01What is ABBV Stock?
02Financial Performance of ABBV Stock
03Innovations and Research
04Market Presence and Global Impact
05Stock Performance and Investor Relations
06Final Thoughts on ABBV Stock

What is ABBV Stock?

ABBV stock represents AbbVie Inc., a biopharmaceutical company that originated from Abbott Laboratories. Known for its innovative treatments and therapies, AbbVie has made significant strides in the healthcare industry. Here are some fascinating facts about ABBV stock:

  1. AbbVie was founded in 2013 after splitting from Abbott Laboratories, focusing on research-based pharmaceuticals.

  2. Humira is AbbVie's flagship product, generating billions in revenue annually. It's used to treat various autoimmune diseases.

  3. ABBV is listed on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

  4. AbbVie has a market capitalization of over $200 billion, making it one of the largest pharmaceutical companies globally.

  5. The company employs more than 47,000 people worldwide, contributing to its extensive research and development efforts.

  6. AbbVie has a strong dividend history, consistently paying and increasing dividends since its inception.

  7. In 2020, AbbVie acquired Allergan, a global pharmaceutical company, for approximately $63 billion.

Financial Performance of ABBV Stock

Understanding the financial performance of ABBV stock can provide insights into its stability and growth potential. Here are some key financial facts:

  1. AbbVie's revenue for 2022 was approximately $58 billion, showcasing its strong market presence.

  2. The company's net income for 2022 was around $13 billion, reflecting its profitability.

  3. AbbVie's earnings per share (EPS) in 2022 were $7.50, indicating solid earnings growth.

  4. The company has a price-to-earnings (P/E) ratio of around 20, suggesting it is reasonably valued compared to its earnings.

  5. AbbVie has a dividend yield of about 4.5%, making it attractive for income-focused investors.

  6. The company's debt-to-equity ratio is approximately 5.5, indicating a high level of leverage.

  7. AbbVie spends around 17% of its revenue on research and development, emphasizing its commitment to innovation.

Innovations and Research

AbbVie's focus on research and development has led to numerous breakthroughs in medicine. Here are some notable facts about their innovations:

  1. AbbVie has over 200 clinical trials ongoing, exploring treatments for various diseases.

  2. The company has more than 50 new molecular entities (NMEs) in its pipeline, showcasing its robust research efforts.

  3. AbbVie invests over $5 billion annually in R&D, one of the highest in the pharmaceutical industry.

  4. Skyrizi and Rinvoq are two of AbbVie's newer drugs, both showing strong sales growth.

  5. AbbVie collaborates with numerous academic institutions and biotech companies, enhancing its research capabilities.

  6. The company focuses on therapeutic areas such as immunology, oncology, neuroscience, and virology, addressing significant medical needs.

  7. AbbVie has received numerous awards for its innovative treatments, recognizing its contributions to healthcare.

Market Presence and Global Impact

AbbVie's global reach and market presence have a significant impact on healthcare worldwide. Here are some facts highlighting this:

  1. AbbVie's products are available in over 170 countries, ensuring global access to its treatments.

  2. The company has manufacturing facilities in more than 20 countries, supporting its global operations.

  3. AbbVie has a strong presence in emerging markets, contributing to its growth potential.

  4. The company is committed to corporate social responsibility, investing in community health and education programs.

  5. AbbVie has been recognized as one of the best places to work, reflecting its positive workplace culture.

  6. The company has a robust environmental sustainability program, aiming to reduce its carbon footprint.

  7. AbbVie supports numerous patient assistance programs, helping those who cannot afford their medications.

Stock Performance and Investor Relations

Investors closely watch ABBV stock for its performance and potential returns. Here are some key facts about its stock performance:

  1. ABBV stock has delivered an average annual return of around 15% since its inception, outperforming many of its peers.

  2. The stock is a component of the S&P 500 index, reflecting its importance in the market.

  3. AbbVie has a beta of 0.85, indicating lower volatility compared to the overall market.

  4. The company regularly engages with investors, providing transparent and detailed financial reports.

  5. AbbVie has a strong institutional ownership, with major investors including Vanguard, BlackRock, and State Street.

  6. The stock has experienced several splits, making it more accessible to individual investors.

  7. AbbVie has a robust share repurchase program, returning value to shareholders through buybacks.

Final Thoughts on ABBV Stock

ABBV stock offers a mix of stability and growth potential. With a strong portfolio of pharmaceutical products, particularly Humira, ABBV has shown consistent revenue growth. The company's focus on research and development ensures a pipeline of new drugs, which could drive future earnings. Dividend investors will appreciate ABBV's history of regular payouts, making it a solid choice for income. However, it's crucial to consider the risks, like patent expirations and competition. Keeping an eye on market trends and regulatory changes can help investors make informed decisions. ABBV's strategic acquisitions and partnerships also play a significant role in its growth strategy. Overall, ABBV stock presents a balanced opportunity for those looking to invest in the healthcare sector. Whether you're a seasoned investor or just starting, ABBV offers a compelling case for consideration.

Was this page helpful?

Our commitment to delivering trustworthy and engaging content is at the heart of what we do. Each fact on our site is contributed by real users like you, bringing a wealth of diverse insights and information. To ensure the highest standards of accuracy and reliability, our dedicated editors meticulously review each submission. This process guarantees that the facts we share are not only fascinating but also credible. Trust in our commitment to quality and authenticity as you explore and learn with us.